Strand V - Search Results

1

Reconciling healthcare professional and patient perspectives in the development of disease activity and response criteria in connective tissue disease-related interstitial lung diseases.

Saketkoo LA, Mittoo S, Frankel S, LeSage D, Sarver C, Phillips K, Strand V, Matteson EL; OMERACT Connective Tissue Disease–Interstitial Lung Diseases Working Group; OMERACT Connective Tissue Disease-Interstitial Lung Diseases Working Group. Saketkoo LA, et al. Among authors: strand v. J Rheumatol. 2014 Apr;41(4):792-8. doi: 10.3899/jrheum.131251. Epub 2014 Feb 1. J Rheumatol. 2014. PMID: 24488412 Free PMC article. Review.

2

OMERACT II: the biologics perspective.

Strand V. Strand V. J Rheumatol. 1995 Jul;22(7):1415-7. J Rheumatol. 1995. PMID: 7562788 Review.

3

Health status instruments / utilities.

Bellamy N, Boers M, Felson D, Fries J, Furst D, Henry D, Liang M, Lovell D, March L, Strand V, et al. Bellamy N, et al. Among authors: strand v. J Rheumatol. 1995 Jun;22(6):1203-7. J Rheumatol. 1995. PMID: 7674258

4

Biologic agents in autoimmune diseases.

Keystone EC, Strand V. Keystone EC, et al. Among authors: strand v. J Rheumatol. 1996 Apr;23(4):743-6. J Rheumatol. 1996. PMID: 8730137 No abstract available.

5

Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III.

Bellamy N, Kirwan J, Boers M, Brooks P, Strand V, Tugwell P, Altman R, Brandt K, Dougados M, Lequesne M. Bellamy N, et al. Among authors: strand v. J Rheumatol. 1997 Apr;24(4):799-802. J Rheumatol. 1997. PMID: 9101522 Review.

6

Outcome measures to be used in clinical trials in systemic lupus erythematosus.

Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Strand V, et al. J Rheumatol. 1999 Feb;26(2):490-7. J Rheumatol. 1999. PMID: 9972993

7

Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains.

Smolen JS, Strand V, Cardiel M, Edworthy S, Furst D, Gladman D, Gordon C, Isenberg DA, Klippel JH, Petri M, Simon L, Tugwell P, Wolfe F. Smolen JS, et al. Among authors: strand v. J Rheumatol. 1999 Feb;26(2):504-7. J Rheumatol. 1999. PMID: 9972996

8

Imaging in rheumatoid arthritis: results of group discussions.

Molenaar ET, Boers M, van der Heijde DM, Alarcón G, Bresnihan B, Cardiel M, Edmonds J, Felson D, Furst DE, Kirwan J, Lassere M, Paulus H, Rau R, van Riel PL, Scott D, Simon L, Strand V. Molenaar ET, et al. Among authors: strand v. J Rheumatol. 1999 Mar;26(3):749-51. J Rheumatol. 1999. PMID: 10090196

9

Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology.

Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Strand V, et al. Lupus. 2000;9(5):322-7. doi: 10.1191/096120300678828424. Lupus. 2000. PMID: 10878722 Review.

10

Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies.

Woodworth TG, Furst DE, Strand V, Kempeni J, Fenner H, Lau CS, Miller F, Day R, Lipani J, Brooks P. Woodworth TG, et al. Among authors: strand v. J Rheumatol. 2001 May;28(5):1163-9. J Rheumatol. 2001. PMID: 11361207 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

523 results

Search Page